Cargando…

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints

EUCAST has established clinical breakpoints for the six most common Candida species and Cryptococcus neoformans but not for less common yeasts because sufficient evidence is lacking. Consequently, the question “How to interpret the MIC?” for other yeasts often arises. We propose a pragmatic classifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Astvad, Karen Marie Thyssen, Arikan-Akdagli, Sevtap, Arendrup, Maiken Cavling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877802/ https://www.ncbi.nlm.nih.gov/pubmed/35205895 http://dx.doi.org/10.3390/jof8020141

Ejemplares similares

EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
por: Jørgensen, Karin Meinike, et al.
Publicado: (2019)

Spectrophotometric detection of azole-resistant Aspergillus fumigatus with the EUCAST broth microdilution method: is it time for automated MIC reading of EUCAST antifungal susceptibility testing of Aspergillus species?
por: Meletiadis, Joseph, et al.
Publicado: (2022)

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
por: Jørgensen, Karin M., et al.
Publicado: (2022)

Disinfection trials with terbinafine‐susceptible and terbinafine‐resistant dermatophytes
por: Skaastrup, Kristoffer Nagy, et al.
Publicado: (2022)

Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles
por: Jørgensen, René, et al.
Publicado: (2017)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications
por: Rogers, Thomas R, et al.
Publicado: (2022)

Increasing Terbinafine Resistance in Danish Trichophyton Isolates 2019–2020
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Correction: Astvad et al. Increasing Terbinafine Resistance in Danish Trichophyton Isolates 2019–2020. J. Fungi 2022, 8, 150
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility
por: Kahlmeter, Gunnar, et al.
Publicado: (2020)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Updated EUCAST Clinical Breakpoints against Aspergillus, Implications for the Clinical Microbiology Laboratory
por: Guinea, Jesús
Publicado: (2020)

Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?
por: Marchese, Anna, et al.
Publicado: (2012)

Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type Aspergillus fumigatus Isolates
por: Arendrup, Maiken Cavling, et al.
Publicado: (2016)

183. Candidaemia in Children and Importance of Central Venous Catheter Removal
por: Arikan, Kamile, et al.
Publicado: (2019)

Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement
por: Gaur, Priyanka, et al.
Publicado: (2023)

753. Guideline Adherence Predicts Outcomes of Candidemia in Europe: Results from the ECMM Candida III Multinational European study
por: Hoenigl, Martin, et al.
Publicado: (2022)

Invasive aspergillosis in patients with severe COVID-19 pneumonia
por: Helleberg, Marie, et al.
Publicado: (2021)

Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance
por: Jørgensen, Karin Meinike, et al.
Publicado: (2021)

Usefulness of EUCAST rapid antibiotic susceptibility breakpoints and screening cut-off values directly from blood cultures for the inference of β-lactam resistance mechanisms in Enterobacterales
por: Cerrudo, V, et al.
Publicado: (2023)

Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus
por: Arikan-Akdagli, Sevtap, et al.
Publicado: (2018)

New definitions of susceptibility categories EUCAST 2019: clinic application
por: Díaz, Sandra G. Nabal, et al.
Publicado: (2022)

The Influence of Medium Composition on EUCAST and Etest Antifungal Susceptibility Testing
por: Vahedi-Shahandashti, Roya, et al.
Publicado: (2023)

In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
por: Arendrup, Maiken Cavling, et al.
Publicado: (2015)

Early phenotypic detection of fluconazole- and anidulafungin-resistant Candida glabrata isolates
por: Georgiou, Panagiota-Christina, et al.
Publicado: (2022)

Time for Precision: A World Without Susceptibility Breakpoints
por: Bader, Justin C, et al.
Publicado: (2018)

Instruction videos from EUCAST
Publicado: (2020)

Clinical Usefulness of Susceptibility Breakpoints for Yeasts in the Treatment of Candidemia: A Noninterventional Study
por: Lass-Flörl, Cornelia, et al.
Publicado: (2020)

Azole resistance in Aspergillus fumigatus. The first 2‐year's Data from the Danish National Surveillance Study, 2018–2020
por: Risum, Malene, et al.
Publicado: (2022)

Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing
por: Matuschek, Erika, et al.
Publicado: (2022)

Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap
por: Crone, Cornelia Geisler, et al.
Publicado: (2022)

Molecular Identification and Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and EUCAST Guidelines
por: Dabas, Yubhisha, et al.
Publicado: (2017)

Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Test for Enterobacterales-Containing Blood Cultures in China
por: Shan, Yuzhang, et al.
Publicado: (2022)

1597. Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Khan, Ayesha, et al.
Publicado: (2019)

Comparison between EUCAST Broth Microdilution and MIC Strip Test in Defining Isavuconazole In Vitro Susceptibility against Candida and Rare Yeast Clinical Isolates
por: Calvo, Maddalena, et al.
Publicado: (2023)

Impact of Tigecycline’s MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing Klebsiella pneumoniae Bacteraemia Treated with Tigecycline Monotherapy—Validation of 2019′s EUCAST Proposed Breakpoint Changes
por: Papadimitriou-Olivgeris, Matthaios, et al.
Publicado: (2020)

Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms
por: Wolfensberger, Aline, et al.
Publicado: (2013)

EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories
por: Åkerlund, Anna, et al.
Publicado: (2020)

The Emergence of Echinocandin-Resistant Candida glabrata Exhibiting High MICs and Related FKS Mutations in Turkey
por: Sig, Ali Korhan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dhif61a1hojq4lbmohs93p1dsh